文献速递小儿神经外科与脑积水神经肿瘤

1型神经纤维瘤病患者的内镜下第三脑室造瘘术:一项国际多中心经验

Endoscopic Third Ventriculostomy in Patients with Neurofibromatosis Type 1: A Multicenter International Experience.
PubMed 文献 · World Neurosurg · 2017-08-24

这项国际多中心回顾性研究纳入42例因梗阻性脑积水接受内镜下第三脑室造瘘术(ETV)的1型神经纤维瘤病(NF1)患者,常见病因为导水管/顶盖肿瘤(31%)、导水管蹼(26%)及NF相关改变所致导水管狭窄(14%)。10例术前诊断为视路胶质瘤,ETV在32例(76%)中成功,平均随访59.4个月±50.9(范围4个月至15年)。作者认为ETV对经选择的NF1合并梗阻性脑积水患者是安全的治疗,应个体化考虑解剖与病理因素。

要点

  • 42例NF1合并梗阻性脑积水患者接受ETV,32例(76%)成功,平均随访59.4个月±50.9。
  • 常见病因为导水管/顶盖肿瘤31%、导水管蹼26%、NF相关改变所致导水管狭窄14%。
  • 10例术前诊断为视路胶质瘤;ETV失败6例在1个月内、3例在9个月内、1例在4年内。

核心结论

  • 作者认为ETV对经选择的NF1合并梗阻性脑积水患者是安全的治疗,应个体化考虑解剖与病理因素。

研究设计与样本

  • 五中心参与的回顾性研究,经机构审查委员会批准后收集数据与影像。
  • 纳入所有年龄的NF1因梗阻性脑积水接受ETV治疗的患者,排除无术后影像学或临床随访者。
  • 共纳入42例患者;ETV失败定义为脑积水临床或影像学征象复发。

主要发现

  • 脑积水常见病因为导水管/顶盖肿瘤(31%)、导水管蹼(26%)、NF相关改变所致导水管狭窄(14%)。
  • 10例患者术前诊断为视路胶质瘤。
  • ETV失败6例在1个月内、3例在9个月内、1例在4年内被识别。
  • ETV在32例(76%)中成功,平均随访59.4个月±50.9(范围4个月至15年)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hydrocephalus in patients with neurofibromatosis (NF) type 1 is usually obstructive and may arise secondary to tumoral or nontumoral causes. Treatment of hydrocephalus in these patients is often challenging owing to combined pathologies and unique anatomic changes. The use of endoscopic third ventriculostomy (ETV) as treatment has rarely been described in this group. We aimed to characterize indications, considerations, and outcome of ETV in patients with NF 1 gathered in a multicenter international cohort. METHODS: Five centers participated in this retrospective study. Following institutional review board approval, data and images were collected. Patients of all ages with NF 1 who underwent ETV for treatment of obstructive hydrocephalus were included. Patients who had no postoperative radiologic or clinical follow-up were excluded. ETV failure was defined as recurrent clinical or radiologic signs of hydrocephalus. RESULTS: The study included 42 patients. Common etiologies for hydrocephalus were aqueductal/tectal tumor (31%), aqueductal web (26%), and aqueductal stenosis owing to NF-related changes (14%). Ten patients had a preoperative diagnosis of optic pathway glioma. ETV failures were identified in 6 patients within 1 month, in 3 patients within 9 months, and in 1 patient within 4 years. ETV was successful in 32 patients (76%) with a mean follow up of 59.4 months ± 50.9 (range, 4 months to 15 years). CONCLUSIONS: ETV is a safe treatment for selected patients with NF 1 and obstructive hydrocephalus. Individual anatomic and pathologic aspects should be taken into consideration.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Roth J, Ber R, Wisoff JH, et al. Endoscopic Third Ventriculostomy in Patients with Neurofibromatosis Type 1: A Multicenter International Experience. World Neurosurg. 2017. PMID: 28842232. doi:10.1016/j.wneu.2017.08.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。